Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 50 years or older
- People who have been diagnosed with neovascular age-related macular degeneration (a type of eye condition affecting vision — confirm with trial site if unsure whether this applies)
- People for whom a doctor has already decided, as part of normal clinical care, to start treatment with a specific eye injection medicine called aflibercept 8 mg
- People who have signed a consent form agreeing to take part before any data is collected
Who may not be able to join:
- People who are currently taking part in another research study that involves treatments outside of normal clinical care
- People who have a condition that means aflibercept 8 mg is not safe for them to use — for example, an active eye or surrounding-eye infection, severe inflammation inside the eye, or a known allergy to aflibercept or any of its ingredients
- People whose other (non-study) eye has received a different type of anti-VEGF eye injection — other than aflibercept — within the 28 days before enrolling
- People whose eye pressure in the study eye is above 25 mmHg (a measure of fluid pressure inside the eye)
- People who have never previously been treated for this eye condition and who have had any prior treatment in the study eye or any systemic (whole-body) treatment for this condition
- People who have previously been treated for this eye condition and have received an anti-VEGF eye injection in the study eye within the last 28 days
- People who have previously been treated and have had a steroid injection inside the study eye within the last 3 months
- People who have previously been treated and have had a dexamethasone implant (a slow-release steroid device) placed in the study eye within the last 6 months
- People who have previously been treated and currently have any other slow-release drug implant in the study eye
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 13801057408
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The change of best corrected visual acuity (BCVA) from baseline to 12 months（BCVA will be examined under real-world conditions and converted into ETDRS letters. ）
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.